Finally, 'The Pill' for men?

Article

Researchers working together from around the country have identified a compound originally intended to treat cancer that may well become the first male contraceptive agent.

Researchers working together from around the country have identified a compound originally intended to treat cancer that may well become the first male contraceptive agent.

The compound, known as JQ1, makes male mice reversibly infertile without hampering sex drive, altering hormones, or inhibiting future production of healthy offspring, according to a study appearing in the journal Cell.

One of the biggest challenges to developing a male “pill,” according to experts, has been finding an agent that crosses the blood:testis barrier and reaches the area where sperm are produced. A small-molecule inhibitor, JQ1 does so by targeting a testis-specific protein called bromodomain (BRDT).

When male mice are given JQ1, according to the study’s authors, they produce fewer sperm, and those they do produce have reduced motility. In fact, the researchers reported that after 6 weeks of daily injections with the agent, mice sperm counts were down nearly 90%. And only 5% of the remaining sperm were properly motile, compared with 85% in the control mice. After 3 months of treatment, none of the male mice could reproduce, even though mating behavior appeared normal.

All of the males could once again produce offspring between 1 and 3 months after stopping the treatment without any adverse consequences on testosterone or other hormone levels, sexual behavior, sperm count/motility, or the ability to produce healthy offspring. None of the male mice had noticeable side effects, and offspring appeared normal.

The compound was originally developed to target a protein called BRD4, which regulates cell division and is involved in a type of aggressive skin cancer. In fact, the agent is also showing promise in treatment of leukemia, multiple myeloma, and lung cancer.

The compound isn’t ready for testing in humans, but because human and mouse BRDT proteins are so similar, the researchers fully expect that their discovery will one day result in an effective male contraceptive.

Read other articles in this issue of Special Delivery.

Recent Videos
Updated FLUBLOK label expands influenza vaccine options for pregnant women | Image Credit: mass-vaccination-resources.org
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
Mammograms may reveal hidden cardiovascular risks, study finds | Image Credit: providers.ucsd.edu
Erika Hamilton highlights emerging breast cancer trends and advances in treatment | Image Credit: sarahcannon.com
JoAnn Pinkerton discusses elinzanetant's crucial role in VMS therapy | Image Credit: uvahealth.com
Empowering women to take charge of their health | Image Credit: © piecesofi.com - © piecesofi.com - stock.adobe.com.
Supporting women through menopause with knowledge and care | Image Credit: © SHOTPRIME STUDIO - © SHOTPRIME STUDIO - stock.adobe.com.
How fezolinetant revolutionizes non-hormonal menopause therapy | Image Credit: imsociety.org
Gulf War exposures linked to early menopause in women veterans | Image Credit: linkedin.com.
© 2024 MJH Life Sciences

All rights reserved.